Pharmaceutical Business review

Firefly receives Phase II SBIR grant for microRNA Profiling in cancer diagnostics

Firefly will utilize the grant to braden its production capacity and also to assess its microRNA assay.

MicroRNAs are a class of biomarkers which are used as indicators for early diagnosis of cancer and other diseases.

Firefly BioWorks co-founder and CTO Daniel Pregibon said they look forward to work with their academic and industry partners to develop research tools in this field.